Cargando…

Two-in-One Nanoparticle Formulation to Deliver a Tyrosine Kinase Inhibitor and microRNA for Targeting Metabolic Reprogramming and Mitochondrial Dysfunction in Gastric Cancer

Dysregulational EGFR, KRAS, and mTOR pathways cause metabolic reprogramming, leading to progression of gastric cancer. Afatinib (Afa) is a broad-spectrum tyrosine kinase inhibitor that reduces cancer growth by blocking the EGFR family. MicroRNA 125 (miR-125) reportedly diminishes EGFRs, glycolysis,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lo, Yu-Li, Wang, Tse-Yuan, Chen, Chun-Jung, Chang, Yih-Hsin, Lin, Anya Maan-Yuh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504622/ https://www.ncbi.nlm.nih.gov/pubmed/36145507 http://dx.doi.org/10.3390/pharmaceutics14091759

Ejemplares similares

Sepsis-Induced Cardiac Mitochondrial Dysfunction Involves Altered Mitochondrial-Localization of Tyrosine Kinase Src and Tyrosine Phosphatase SHP2
por: Zang, Qun S., et al.
Publicado: (2012)

Cationic PEGylated liposomes incorporating an antimicrobial peptide tilapia hepcidin 2–3: an adjuvant of epirubicin to overcome multidrug resistance in cervical cancer cells
por: Juang, Vivian, et al.
Publicado: (2016)

Enhancing Anticancer Effect of Gefitinib across the Blood–Brain Barrier Model Using Liposomes Modified with One α-Helical Cell-Penetrating Peptide or Glutathione and Tween 80
por: Lin, Kuan-Hung, et al.
Publicado: (2016)

Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides
por: Hong, Shu-Ting, et al.
Publicado: (2019)

Reprogramming signal transduction through a designer receptor tyrosine kinase
por: Kongkrongtong, Tatphon, et al.
Publicado: (2021)

Systems Modeling Identifies Divergent Receptor Tyrosine Kinase Reprogramming to MAPK Pathway Inhibition
por: Claas, Allison M., et al.
Publicado: (2018)

Tyrosine kinase inhibitors reprogramming immunity in renal cell carcinoma: rethinking cancer immunotherapy
por: Aparicio, L. M. A., et al.
Publicado: (2017)

Metabolic Reprogramming in Response to Alterations of Mitochondrial DNA and Mitochondrial Dysfunction in Gastric Adenocarcinoma
por: Chang, Tzu-Ching, et al.
Publicado: (2022)

Integrated molecular signaling involving mitochondrial dysfunction and alteration of cell metabolism induced by tyrosine kinase inhibitors in cancer
por: Rodríguez-Hernández, María A., et al.
Publicado: (2020)

Fyn Tyrosine Kinase as Harmonizing Factor in Neuronal Functions and Dysfunctions
por: Matrone, Carmela, et al.
Publicado: (2020)

Tyrosine kinase inhibitors induced thyroid dysfunction: myth or reality?
por: Malhotra, Anjli, et al.
Publicado: (2023)

Mitochondrion-Directed Nanoparticles Loaded with a Natural Compound and a microRNA for Promoting Cancer Cell Death via the Modulation of Tumor Metabolism and Mitochondrial Dynamics
por: Lo, Yu-Li, et al.
Publicado: (2020)

The RON Receptor Tyrosine Kinase Promotes Metastasis by Triggering MBD4-Dependent DNA Methylation Reprogramming
por: Cunha, Stéphanie, et al.
Publicado: (2014)

Protein–Protein Conjugates: Tyrosine Delivers
por: Geeson, Michael B., et al.
Publicado: (2020)

Acrolein induces mtDNA damages, mitochondrial fission and mitophagy in human lung cells
por: Wang, Hsiang-Tsui, et al.
Publicado: (2017)

Ras-ERK-ETS inhibition alleviates neuronal mitochondrial dysfunction by reprogramming mitochondrial retrograde signaling
por: Duncan, Olivia F., et al.
Publicado: (2018)

Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities
por: Kleczko, Emily K., et al.
Publicado: (2018)

Expression of AXL receptor tyrosine kinase relates to monocyte dysfunction and severity of cirrhosis
por: Brenig, Robert, et al.
Publicado: (2019)

Hepatocellular Toxicity Associated with Tyrosine Kinase Inhibitors: Mitochondrial Damage and Inhibition of Glycolysis
por: Paech, Franziska, et al.
Publicado: (2017)

Systems Analysis of Drug-Induced Receptor Tyrosine Kinase Reprogramming Following Targeted Mono- and Combination Anti-Cancer Therapy
por: Goltsov, Alexey, et al.
Publicado: (2014)

Acetoacetate protects macrophages from lactic acidosis-induced mitochondrial dysfunction by metabolic reprograming
por: Adam, Clément, et al.
Publicado: (2021)

Tyrosine Kinases in Cancer
por: Blau, Olga, et al.
Publicado: (2015)

MicroRNAs as the critical regulators of tyrosine kinase inhibitors resistance in lung tumor cells
por: Maharati, Amirhosein, et al.
Publicado: (2022)

The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
por: Wu, Shang-Gin, et al.
Publicado: (2016)

MicroRNAs Dysregulation and Mitochondrial Dysfunction in Neurodegenerative Diseases
por: Catanesi, Mariano, et al.
Publicado: (2020)

URI alleviates tyrosine kinase inhibitors-induced ferroptosis by reprogramming lipid metabolism in p53 wild-type liver cancers
por: Ding, Zhiwen, et al.
Publicado: (2023)

NEAP/DUSP26 suppresses receptor tyrosine kinases and regulates neuronal development in zebrafish
por: Yang, Chi-Hwa, et al.
Publicado: (2017)

Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases
por: Stern, David F
Publicado: (2000)

Targeting Spleen Tyrosine Kinase-Bruton's Tyrosine Kinase Axis for Immunologically Mediated Glomerulonephritis
por: Chen, Jin-Shuen, et al.
Publicado: (2014)

Pyk2 is a Novel Tau Tyrosine Kinase that is Regulated by the Tyrosine Kinase Fyn
por: Li, Chuanzhou, et al.
Publicado: (2018)

BY-kinases: Protein tyrosine kinases like no other
por: Hajredini, Fatlum, et al.
Publicado: (2022)

MicroRNA Expression Profiling of Lung Cancer with Differential Expression of the RON Receptor Tyrosine Kinase
por: Ou, Huilin, et al.
Publicado: (2021)

Inflexibility of AMPK-mediated metabolic reprogramming in mitochondrial disease
por: Lin, Dar-Shong, et al.
Publicado: (2017)

Tyrosine kinases in rheumatoid arthritis
por: Okamoto, Hiroshi, et al.
Publicado: (2011)

Tyrosine Kinase Inhibitors and Interferon
por: Dimou, Maria, et al.
Publicado: (2014)

Tyrosine Kinase Inhibitors for the Elderly
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2016)

Receptor tyrosine kinases in carcinogenesis
por: Zhang, Xiao-Ying, et al.
Publicado: (2016)

Tyrosine Kinase Inhibitors and Pregnancy
por: Abruzzese, Elisabetta, et al.
Publicado: (2014)

Receptor tyrosine kinases in carcinogenesis
por: Zhang, Xiao-Ying, et al.
Publicado: (2020)

Tyrosine Kinase Receptors in Oncology
por: Esteban-Villarrubia, Jorge, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1364l2op6delv6093qlvtgshrj